REVIEW

Lymphocytic interstitial pneumonitis in HIV infected adults

S Das, R F Miller

Sex Transm Infect 2003;79:88-93

See end of article for authors' affiliations

Correspondence to:
Dr R Miller, Department of
Sexually Transmitted
Diseases, Windeyer
Institute of Medical
Sciences, Royal Free and
University College Medical
School and Camden
Primary Care Trust,
Mortimer Market Centre,
Mortimer Market, London
WC1E 6AU, UK;
rmiller@gum.ucl.ac.uk

Accepted for publication
10 October 2002

Objectives: To describe current knowledge on the aetiology, pathology, presentation, diagnosis, and treatment of lymphocytic interstitial pneumonitis in HIV infected adults.

Methods: A Medline search was performed using the key words "HIV," "pneumonitis," and "lymphocytes." A further search was performed with the MESH heading "interstitial lung disorders." Related articles were also searched using Pubmed.

Results: Lymphocytic interstitial pneumonitis is a common complication in HIV infected children. In adults it is uncommon and is described most commonly among black African and Afro-Caribbean patients. The aetiology and pathogenesis of lymphocytic interstitial pneumonitis in HIV infection is not clear. The clinical and radiological presentations may be indistinguishable from *Pneumocystis carinii* infection and a lung biopsy is necessary to establish the diagnosis. Recent evidence suggests that lymphocytic interstitial pneumonitis in HIV infected patients may respond to combination antiretroviral therapy with dramatic improvements in clinical and radiological abnormalities.

Conclusion: Lymphocytic interstitial pneumonitis in HIV infected patients is a treatable condition. This condition should be considered in HIV infected patients presenting with respiratory symptoms as they may gain considerable benefit from antiretroviral therapy.

Infection and malignancy are common causes of interstitial lung disorders in HIV infected individuals. However, some HIV infected patients develop symptomatic non-infectious inflammatory interstitial lung disease. At one end of the spectrum is non-specific interstitial pneumonitis, which is common in adults, and at the other end is lymphocytic interstitial pneumonitis, which is common in children and less frequently described in HIV infected adults.¹⁻⁴ Both non-specific and lymphocytic interstitial pneumonitis present with clinical and radiological abnormalities that may mimic opportunistic pulmonary infection, especially *Pneumocystis carinii* pneumonia. Patients frequently receive empirical anti-infective therapy before the correct diagnosis is made by lung biopsy.⁴

Before the start of the HIV pandemic, lymphocytic interstitial pneumonitis had been described in case reports in association with a wide range of abnormalities. With the advent of AIDS, it soon became clear that lymphocytic interstitial pneumonitis was being described with increasing frequency, particularly in black African and Afro-Caribbean HIV infected patients. This article reviews current knowledge on the aetiology, pathology, presentation, diagnosis, and treatment of lymphocytic interstitial pneumonitis in HIV infected adults.

METHODS

A Medline search from 1996 to August 2002 was performed using the key words "HIV," "pneumonitis," and "lymphocytes." A further search was performed with the MeSH heading "interstitial lung disorders." A total of 328 articles were found with the combination of "HIV" and "pneumonitis," and the search was limited to the English language, resulting in 262 articles. This search was further focused on articles dealing with lymphocytic interstitial pneumonitis and non-specific interstitial pneumonitis, and 152 articles were identified. A further search was made through Pubmed using the key word "lymphocytic interstitial pneumonitis," which resulted in 64 articles and the search was extended to include related articles, which identified another 34 articles. A search with the key word "lymphocytic interstitial pneumonitis" was also made using Medline, resulting in 106 articles. Ultimately, 228 articles were reviewed.

HISTORY AND EPIDEMIOLOGY

Lymphocytic interstitial pneumonitis was first described in 1996,⁵ and may be associated with a variety of autoimmune and lymphoproliferative disorders including Sjögren's syndrome,^{6,7} myasthenia gravis,⁸ systemic lupus erythematosus,⁹ pernicious anaemia,¹⁰ rheumatoid arthritis, Hashimoto's thyroiditis, lymphoma,⁷ autoerythrocyte sensitisation syndrome,¹¹ chronic active hepatitis, biliary cirrhosis,¹² and multicentric Castleman's disease.¹³ It may also be associated with ataxia-telangiectasia,¹⁴ pulmonary alveolar proteinosis, complicated by *Mycobacterium avium-intracellulare* infection,¹⁵ and various immune deficiency states including agammaglobulinaemia,¹⁰ hypogammaglobulinaemia,¹² and common variable immunodeficiency.¹⁶

An association with retroviral infection was first described in 1986 in relation to HIV-1.¹⁷⁻¹⁹ While common in the HIV infected paediatric population,²⁰ it appears to be uncommon in adults, occurring in <5% of necropsy case series.²¹ Of note, HIV infected children with haemophilia are less commonly affected than children who acquire HIV infection by vertical transmission. This may reflect that few children infected with HIV by blood products were black African or Afro-Caribbean.²² An association with HIV-2, although rare, has also been reported.²³ Lymphocytic interstitial pneumonitis has also been described in association with HTLV-1 infection in the absence of HIV infection.²⁴ In HIV infected adults, lymphocytic interstitial pneumonitis has been described in patients from all risk groups although it is most common in black Africans and Afro-Caribbean patients. It appears particularly common in those from Haiti but this may be because the condition has been specifically looked for in this group of patients.^{25,26} In contrast, it is rare in white homosexuals.^{2,19,25}

AETIOLOGY AND PATHOGENESIS

HIV associated lymphocytic interstitial pneumonitis may represent part of a spectrum of lymphocytic infiltrative disorders.^{1,4,25,27-29} Most HIV infected adult patients develop a low grade lymphocytic alveolitis which is usually asymptomatic.^{30,31} Some progress to symptomatic alveolitis, either non-specific interstitial pneumonitis or lymphocytic

interstitial pneumonitis. It appears that lymphocytic alveolitis, non-specific interstitial pneumonitis, and lymphocytic interstitial pneumonitis represent a spectrum of lymphoid pneumonitis. Why pulmonary lymphocytic infiltrates in some HIV infected patients manifest as non-specific interstitial pneumonitis rather than lymphocytic interstitial pneumonitis or vice versa remains unclear. It may be that different clades of HIV determine whether a patient develops non-specific interstitial pneumonitis or lymphocytic interstitial pneumonitis.²⁹

An association with major histocompatibility complex antigens has been demonstrated. Those with HLA-DR5 and HLA-DR6 in black and HLA-DR7 in white patients are predisposed to develop a systemic lymphocytosis of CD8 T cells with clinically significant diffuse visceral infiltration, known as diffuse infiltrative lymphocytosis syndrome (DILS).³²⁻³³ Involved organs include lung, kidney, liver, stomach, meninges, cranial nerves, motor neurons, parotid and other salivary and lacrimal glands, nasopharynx, bone marrow, spleen, colon, duodenum, thymus, and uvea.^{1 32-36}

Possible mechanisms responsible for accumulation of lymphocytes in the pulmonary interstitium include recruitment of circulatory lymphocytes in response to chemoattractants, decreased efflux of cells away from the lung,²⁷ and an in situ lymphoproliferative response to chronically presented viral antigens or to locally elaborated cytokines, including interleukin 2 and TNF α .^{27 37}

The term bronchus associated lymphoid tissue (BALT) describes pulmonary mucosal lymphoid tissue.³⁸⁻⁴⁰ The development and expansion of BALT is a response to local stimulation from inflammation and inhalation of antigens.²⁵ In the normal lung BALT is seldom seen, being found in fetal and infant lung, and only when evidence of antigenic stimulation was present.⁴¹ In a necropsy study in HIV non-infected patients, expression of BALT was more common in smokers than in non-smokers (82% v 14%). Both T and B lymphocytes have been found within the cell population of BALT.⁴² It is possible that viral factors, acting with HIV-1, may be one of several factors responsible for the appearance and development of BALT and may also be involved in the immunopathogenesis of lymphoproliferative disorders of the lung seen in HIV infected patients.²⁵

Several studies have demonstrated the presence of Epstein-Barr virus (EBV) DNA in lung biopsy specimens from HIV infected children with lymphocytic interstitial pneumonitis.⁴³⁻⁴⁵ Correlation between lymphocytic interstitial pneumonitis and serological evidence of active infection with EBV has also been demonstrated.^{28 46} Studies in vitro have shown that EBV may immortalise and transform B cells into lymphoblastoid cells by upregulation of the cellular proto-oncogene, B cell leukaemia-2 (bcl-2) via the latent membrane protein (LMP-1).⁴⁷ The presence of EBV LMP-1 protein in airway epithelial cells and overexpression of the cellular bcl-2 protein in lymphoid cells of lung tissue has been demonstrated in patients with lymphocytic interstitial pneumonitis.⁴⁸ By contrast, EBV activity has not been detected in lung biopsy specimens from adult HIV patients with lymphocytic interstitial pneumonitis in other studies.^{24 35}

Other evidence suggests that HIV infection itself may be involved in the development of lymphocytic interstitial pneumonitis.^{27 37} Induction of a lymphocytic interstitial pneumonitis-like syndrome by HIV-1 has been shown in a transgenic mouse model.⁴⁹ In vitro EBV infected B cells are particularly susceptible to infection by HIV and may facilitate HIV replication in the lung.⁵⁰ By in situ hybridisation, large amounts of HIV RNA have been detected within the germinal centres of lymphoid tissue in an adult HIV infected patient with lymphocytic interstitial pneumonitis.⁵⁰ In another patient, p24 antigen was detected in macrophages and the interstitium of a lung biopsy specimen.³ Other reports describe detection of both HIV antigen and antibody in bronchoalveolar lavage (BAL) fluid of patients with lymphocytic inter-

stitial pneumonitis.⁴⁰ In one study, the ratio of HIV specific IgG/total IgG in BAL fluid was higher than in peripheral blood in patients with lymphocytic interstitial pneumonitis. The ratio was lower in patients with other diagnoses.^{40 51} Aberrant expression of immunoglobulin heavy chain genes in EBV negative, HIV related lymphocytic interstitial pneumonitis has been demonstrated.⁵¹ These observations suggest that lymphocytic interstitial pneumonitis may be associated with a local humoral response within tissue evoked by HIV infection.^{40 51 52} A spectrum of pulmonary lymphoproliferative syndromes, including lymphocytic interstitial pneumonitis has been described in patients infected with human T lymphotropic virus-1.^{1 50 53 54}

CLINICAL FEATURES

The most common symptoms of lymphocytic interstitial pneumonitis include non-productive cough and progressive exertional dyspnoea of several weeks' duration.^{1 3 12 25} Fever, weight loss, and fatigue are frequently reported.^{1 12 25} Pleuritic chest pain and haemoptysis are uncommon and suggest either an alternative diagnosis or that co-pathology is present. Some patients with lymphocytic interstitial pneumonitis may be asymptomatic or have minimal symptoms and the diagnosis is only suggested by the finding of an abnormal chest radiograph (see below). Clubbing is common in children with lymphocytic interstitial pneumonitis and is thought to be secondary to lymphocytic interstitial pneumonitis induced bronchiectasis.³⁵ Recently, clubbing has been described in an adult in the absence of bronchiectasis.³ Generalised lymphadenopathy, hepatosplenomegaly, and parotid enlargement are more common in children. In the chest, bi-basal end inspiratory crackles are a consistent finding on lung auscultation. Wheeze and diminished breath sounds may also be present. In many instances, the physical findings are minimal or the physical examination is normal.^{1 3 12 25} Some patients with lymphocytic interstitial pneumonitis may present with respiratory symptoms and features of Sjögren's syndrome^{32 33} as part of DILS.

DIAGNOSIS

Clinical and laboratory abnormalities, although highly suggestive, are not specific for lymphocytic interstitial pneumonitis.^{1 3 12 25} Measurement of serum LDH enzyme levels is not helpful,¹ as elevations are also observed in other conditions, including *Pneumocystis carinii* pneumonia, pulmonary embolism, bacterial pneumonia, non-specific interstitial pneumonitis, and lymphoma.¹ Dysproteinaemia, usually a polyclonal hypergammaglobulinaemia on serum electrophoresis is common^{1 25 26}; IgG is the most frequently elevated immunoglobulin.¹² These abnormalities are also described in asymptomatic HIV infection and so they do not aid diagnosis.

On the plain chest radiograph, an interstitial pattern is commonly seen. This characteristically shows bilateral reticular and ground glass opacities predominantly in the lung bases. These appearances may be difficult to distinguish from infectious causes of a diffuse pneumonitis, including *Pneumocystis carinii* pneumonia and bacterial pneumonia (fig 1), and from non-specific interstitial pneumonitis. The chest radiographic abnormalities occurring in lymphocytic pneumonitis have been divided into three radiographic patterns. In type 1, fine reticular or reticulonodular opacities thought to be due to lymphocytic infiltration of the interstitium are seen. In type 2, further accumulation of lymphocytes is thought to produce larger reticulonodular infiltrate nodules having diameters of between 3 and 5 mm. These appearances may mimic miliary tuberculosis (fig 2). The type 3 pattern is a combination of types 1 and 2, with superimposed areas of alveolar opacities. These alveolar opacities are believed to result from bronchiolar compression caused by more severe lymphocytic infiltration.⁵⁶ Lymphocytic infiltration of the submucosa of the respiratory

Figure 1 Chest radiograph showing extensive bilateral interstitial infiltrates with ground glass shadowing. Black African HIV positive male, CD4 count 200 cells $\times 10^6/l$, presented with 2 months of increasing dyspnoea, non-productive cough, and fever. Thought initially to have *Pneumocystis carinii* pneumonia but bronchoscopy negative and patient failed to respond to high dose co-trimoxazole. Open lung biopsy revealed lymphocytic interstitial pneumonitis.

Figure 2 Chest radiograph showing widespread miliary shadowing. Black African HIV positive male, CD4 count 480 cells $\times 10^6/l$ (12%) presented with 4 weeks of increasing exertional dyspnoea and non-productive cough. Bronchoscopy was negative and open lung biopsy showed lymphocytic interstitial pneumonitis.

bronchioles may lead to obstruction, inflammation, atelectasis, fibrosis, and finally to bronchiectasis.⁵⁷ Pleural effusions are uncommon in adults.^{1 25 58} Hilar and mediastinal lymph node enlargement is more common than previously recognised.^{56 57}

High resolution computer tomography reveals the extent of the disease and may also demonstrate bronchiectasis and the degree of fibrosis.^{55 57-59} Typical appearances include interstitial infiltrates, ground glass shadowing, and centrilobular nodules³ (figs 3 and 4). These appearances have a wide differential diagnosis including extrinsic allergic alveolitis due to bird fancier's lungs, sarcoidosis, Kaposi's sarcoma, tuberculosis, fungal infections, and *Pneumocystis carinii* pneumonia.³ Computer tomography may also help discriminate between fibrotic and reversible inflammatory disease.^{60 61}

Imaging of the lung using the radionuclide gallium-67 has been performed in patients with lymphocytic interstitial pneumonitis.^{2 26 33} Several patterns of intrapulmonary uptake have been described, these include focal and diffuse uptake and no uptake within the lung. These appearances have been described not only in lymphocytic interstitial pneumonitis but also in patients with *Pneumocystis carinii* pneumonia, bacterial pneumonia, and mycobacterial infections. Thus, patterns of gallium-67 uptake in the lung do not aid in diagnosis.⁵¹ High

Figure 3 High resolution computed tomograph through the lung bases showing patchy ground glass shadowing. White HIV positive male, CD4 count 500 cells $\times 10^6/l$, presented with 6 months increasing exertional dyspnoea. Bronchoscopy was negative for *Pneumocystis carinii* and other pathogens. Open lung biopsy revealed lymphocytic interstitial pneumonitis.

Figure 4 High resolution computed tomograph through the lungs, just below the level of the carina, showing extensive miliary shadowing mimicking *M tuberculosis*. Same patient as figure 2.

resolution computer tomography is more helpful than gallium-67 scanning in guiding the method of biopsy and directing the bronchoscopist to the diseased lung segment in order to maximise diagnostic yield.^{62 63}

Pulmonary function tests usually demonstrate a restrictive pattern with a reduced or normal total lung diffusion capacity.^{1 3 12 40} Obstructive airway disease has occasionally been reported.⁶⁴ Arterial blood gas measurements are unhelpful as they may reveal a normal P_{aO_2} , or mild to profound hypoxaemia with an increased alveolar to arterial oxygen gradient,¹² findings that also occur in *P carinii* pneumonia⁶⁵ and other infectious causes of a diffuse pneumonitis. The diagnosis of lymphocytic interstitial pneumonitis is made by transbronchial or open lung biopsy.^{1 3 4 29} The diagnostic yield from transbronchial biopsy is lower than that from open lung biopsy and the procedure may result in a pneumothorax. Open lung biopsy may be needed in the case of non-specific findings from transbronchial biopsy and is the preferred method of obtaining lung tissue in many centres.^{3 29 65}

Macroscopically, the lungs and the pleura appear normal.²⁹ Microscopically, diffuse linear interstitial thickening with occasional distinct nodules or follicles, some of them adjacent to the airways and pulmonary arteries, are seen^{29 56}; rarely areas of confluence occur. Histological features range from diffuse interstitial infiltrates of lymphocytes, plasma cells, and histiocytes,^{29 56 66 67} to more patchy, dense cellular infiltrates with lymphoid follicles and germinal centres. The lymphocytes are usually polyclonal and demonstrate different stages of activation.^{29 56 66 67} Giant cells and histiocytes may also be seen.⁶⁷ In areas of follicular predominance, immunoblasts and histiocytes containing cytoplasmic cellular debris may be found.²⁹ Non-caseating granulomata have been reported in between 20–50% of cases.^{3 12 29 56 66 67} Of note, no vasculitis or

necrosis is found and other findings include hyperplasia of type 2 pneumocytes.^{4 29 67} The infiltrate usually involves the alveolar septae, subpleural areas, intralobular septae and lymphatics running along the bronchovascular bundles. In some cases, the lymphocytic infiltration may be extensive, extending to and consolidating the alveoli.^{29 56 66 67} Lymphocytic infiltration in the bronchiolar walls has been demonstrated in only a few cases.^{3 29} The lymphoid aggregates may impinge on the walls of the terminal and respiratory bronchioles, producing variable degrees of bronchiolar stenosis and a clinical picture consistent with bronchiolitis.^{29 56} With chronicity, lymphocytes may be replaced with fibrosis, and airspace consolidation may be replaced with honeycombing and centrilobular nodules with cysts.^{29 56 66-68} The histology of lymphocytic interstitial pneumonitis differs from non-specific interstitial pneumonitis mainly in the extent and volume of cellular infiltration and the association with secondary type 2 pneumocyte hyperplasia. Histologically, the distinction between these two conditions may not always be clear cut.^{4 29}

The differential diagnosis histologically includes other disorders that are characterised by interstitial lymphoid proliferation. *P. carinii* pneumonia may induce a predominantly lymphoplasmacytic infiltrate and may be erroneously diagnosed as lymphocytic interstitial pneumonitis.^{67 68} Fungal and mycobacterial infections should be excluded when histiocytic proliferation and granulomata formation become prominent.⁶⁸ In the latter stages of lymphocytic interstitial pneumonitis, the prominent interstitial fibrosis may be difficult to distinguish from cryptogenic fibrosing alveolitis, and other common types of interstitial pneumonitis.⁶⁷⁻⁶⁹

NATURAL HISTORY

HIV associated lymphocytic interstitial pneumonitis usually occurs when the CD4+ T lymphocyte count is still within the normal range.^{3 4 32 33} By contrast, non-specific interstitial pneumonitis usually occurs at a later stage, patients typically have CD4+ T lymphocyte counts around 200 cells $\times 10^6/L$.^{4 25} However, both conditions have been reported in patients whose CD4+ T lymphocyte counts are within the normal range.^{1 4 25}

The natural history of lymphocytic interstitial pneumonitis is variable.^{1 25} The duration of symptoms at the time of diagnosis of HIV associated lymphocytic interstitial pneumonitis is between 1 month and 11 years.¹ Symptoms are usually progressive, but may remain stable for months without treatment and sometimes improve spontaneously.⁷⁰ Mortality data are inexact, in part this is due to lack of reported follow up and in part to the anecdotal nature of some reports. By contrast, most cases of non-specific pneumonitis resolve spontaneously, usually do not develop respiratory insufficiency, and do not themselves lead to death.^{1 4 25}

TREATMENT

As the clinical course of lymphocytic interstitial pneumonitis is unpredictable, assessment of specific therapeutic interventions is difficult. In the general population, before AIDS, response of lymphocytic interstitial pneumonitis to immunosuppression with glucocorticoids was poor or irregular.^{1 7 9 71} A combination of glucocorticoids and additional immunosuppression with azathioprine was successful in a single case.⁷²

In HIV infected patients assessment of the prognosis and outcome of lymphocytic interstitial pneumonitis is made more difficult because the illness is significantly affected by the natural history and response to treatment of the underlying HIV infection. Several reports from before antiretroviral therapy became available describe no deterioration in lymphocytic interstitial pneumonitis without specific intervention.²⁵ In contrast with the general population, other reports of HIV infected patients with lymphocytic interstitial pneumonitis describe improvements in most cases in response

to glucocorticoids.^{32-33 73-75} In these reports, the dose and duration of glucocorticoid therapy is variable with therapy being given from several weeks only to chronic suppressive therapy.^{32 33 73-75} Some reports describe an initial response with relapse on withdrawal or dose reduction of glucocorticoids. More aggressive immunosuppression using chlorambucil has been reported as successful in a single case.^{32 33}

The response of HIV associated lymphocytic interstitial pneumonitis to intervention with antiretroviral therapy is variable. Zidovudine, as monotherapy, has been used in three patients.^{76 77} In two patients a response was observed,⁷⁴ in a third patient with more advanced HIV infection no response occurred.^{77 78} One report described significant improvement with chloroquine in a child with lymphocytic interstitial pneumonitis.⁷⁸ Of note, the patient was also receiving zidovudine. Recently, improvement in clinical symptoms, radiology and pulmonary function tests have been described in an HIV infected adult patient with lymphocytic interstitial pneumonitis treated with combination antiretroviral therapy (consisting of three nucleoside analogues). The improvement in lymphocytic interstitial pneumonitis was paralleled by reduction of HIV viral load to below the limits of detection and by improvement in CD4+ T lymphocyte counts.³ There are no reports of treatment of lymphocytic interstitial pneumonitis with protease inhibitor or non-nucleoside reverse transcriptase inhibitor containing regimens of antiretroviral therapy, but hypothetically, as these combinations are more effective in lowering the HIV viral load and increasing the CD4+ T lymphocyte count,⁷⁹ they might be expected to bring about improvement in the clinical course of lymphocytic interstitial pneumonitis.

CONCLUSION

Lymphocytic interstitial pneumonitis was rarely encountered by clinicians before the onset of the HIV pandemic. The clinical presentation, findings on examination, chest radiographic and laboratory abnormalities may be difficult to distinguish from infectious causes of diffuse pneumonitis which occur more commonly in the HIV infected adult. Lung biopsy is required in order to make a diagnosis. Treatment of the underlying HIV infection with combination antiretroviral therapy may have a beneficial effect on the symptoms and prognosis of lymphocytic interstitial pneumonitis.

CONTRIBUTORS

SD and RFM jointly proposed the project; SD carried out the literature search and wrote the first draft of the manuscript; RFM critically commented on subsequent drafts and co-wrote the final version of the manuscript with SD.

Source of funding: None.

Conflict of interest: None.

Authors' affiliations

S Das, Department of Genitourinary and HIV Medicine, Whittall Street Clinic, Whittall Street, Birmingham B4 6DH, UK

R F Miller, Department of Sexually Transmitted Diseases, Windeyer Institute of Medical Sciences, Royal Free and University College Medical School and Camden Primary Care Trust, Mortimer Market Centre, Mortimer Market, London WC1E 6AU, UK

REFERENCES

- 1 **Saukkonen JJ**, Farber HW. Lymphocytic interstitial pneumonitis. In: Zumla A, Johnson M, Miller RF, eds. *AIDS and respiratory medicine*. Chapter 21. London: Chapman and Hall 1997:331-43.
- 2 **Conces DJ**, Tarver RD. Non-infectious and non-malignant pulmonary disease in AIDS. *J Thorac Imaging* 1991;6:53-9.
- 3 **Scarborough M**, Shaw P, Miller RF. Lymphocytic interstitial pneumonitis in an HIV-infected adult: response to antiretroviral therapy. *Int J STD AIDS* 2000;11:119-22.

- 4 Griffiths MH, Miller RF, Semple SJG. Interstitial pneumonitis inpatients infected with the human immunodeficiency virus. *Thorax* 1995;**50**:1141-6.
- 5 Carrington C, Liebow A. Lymphocytic interstitial pneumonia. *Am J Pathol* 1996;**48**:36 (abstract).
- 6 Strimlan C, Rosenow E, Divertie M, et al. Pulmonary manifestations of Sjogren's syndrome. *Chest* 1976;**70**:354-61.
- 7 Strimlan C, Rosenow C, Weiland L, et al. Lymphocytic interstitial pneumonitis: a review of 13 cases. *Ann Intern Med* 1978;**88**:616-21.
- 8 Montes M, Tomasi T, Noehren T. Lymphoid interstitial pneumonia with monoclonal gammopathy. *Am Rev Respir Dis* 1968;**98**:277-80.
- 9 Liebow A, Carrington C. Diffuse pulmonary lymphoreticular infiltration associated with dysproteinemia. *Med Clin N Am* 1973;**57**:809-43.
- 10 Levinson A, Hopewell P, Stites D, et al. Coexistent lymphocytic interstitial pneumonia, pernicious anaemia and agammaglobulinaemia; comment on autoimmune pathogenesis. *Arch Intern Med* 1976;**136**:213-16.
- 11 DeCoteau W, Tourville D, Ambrus J, et al. Lymphoid interstitial pneumonia and autoerythrocyte sensitization syndrome. *Arch Intern Med* 1974;**134**:519-22.
- 12 Koss MN, Hochholzer L, Langloss JM, et al. Lymphocytic interstitial pneumonia. Clinicopathological and immunopathological findings in 18 cases. *Pathology* 1987;**19**:178-85.
- 13 Jonkoh T, Müller NL, Ichikado K, et al. Intrathoracic multicentric Castleman's disease. CT findings in 12 patients. *Radiology* 1998;**209**:477-81.
- 14 Tangsinmankong N, Wayne AS, Howenstine MS, et al. Lymphocytic interstitial pneumonitis, elevated IgM concentration, and hepatosplenomegaly in ataxia-telangiectasia. *J Pediatr* 2001;**138**:939-41.
- 15 Bakhsos R, Gattuso P, Arcot C, et al. Pulmonary alveolar proteinosis: an unusual association with Mycobacterium avium intracellulare infection and lymphocytic interstitial pneumonia. *South Med J* 1996;**89**:801-2.
- 16 Popa V. Lymphocytic interstitial pneumonitis of common variable immunodeficiency. *Ann Allergy* 1988;**60**:203-6.
- 17 Oleske J, Minnefor A, Cooper R, et al. Immune deficiency syndrome in children. *JAMA* 1983;**249**:2345-9.
- 18 Rubinstein A, Sicklick M, Gupta A, et al. Acquired immune deficiency with reversed T4/T8 ratios in infants born to promiscuous and drug addicted mothers. *JAMA* 1986;**249**:2350-6.
- 19 Saldana M, Montes J, Buck B. Lymphoid interstitial pneumonia in Haitian residents of Florida. *Chest* 1983;**84**:347 (abstract).
- 20 Joshi V, Oleske J, Minnefor A, et al. Pathology of suspected AIDS in children. *Pediatr Pathol* 1987;**2**:71-87.
- 21 Marchevsky A, Rosen M, Chrystal G, et al. Pulmonary complications of AIDS: a clinicopathologic study of 70 cases. *Human Pathol* 1985;**16**:659-70.
- 22 Jason J, Stehr-Green J, Holman R, et al. HIV infection in hemophilic children. *Pediatrics* 1988;**82**:565-70.
- 23 Couderc LJ, Brun-Vezinet F, Rey MA, et al. Lymphoid interstitial pneumonitis and infection with human immunodeficiency virus type 2. *Chest* 1991;**99**:1320.
- 24 Setoguchi Y, Takahashi G, Nokwa K. Detection of human T-cell leukemia virus-1 related antibodies in patients with lymphocytic interstitial pneumonia. *Am Rev Resp Dis* 1991;**144**:1361-5.
- 25 Semple SJG. Non-neoplastic lymphoproliferative disorders of the lung. In: Semple SJG, Miller R, eds. *AIDS and the lung*. Chapter 9. Oxford: Blackwell Science, 1997:182-90.
- 26 Couderc LJ, Herve P, Solal-Celigny P, et al. Interstitial lymphoid pneumonia and polyadenopathies in patients infected with the LAV/HTLV III virus. *Presse Med* 1986;**15**:1127-30.
- 27 Semenzato G. Immunology of interstitial lung diseases: cellular events taking place in the lung of sarcoidosis, hypersensitivity pneumonitis and HIV infection. *Eur Resp J* 1991;**4**:94-104.
- 28 Koss MN. Pulmonary lymphoid disorders. *Sem Diagn Pathol* 1995;**12**:158-71.
- 29 Travis WD, Fox CH, Davancy KO. Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus non-specific interstitial pneumonitis. *Hum Pathol* 1992;**23**:529-41.
- 30 Semenzato G, Agostini C. HIV-related interstitial lung disease. *Curr Opin Pulmon Med* 1995;**1**:383-91.
- 31 Agostini C, Semenzato G. Immunologic effects of HIV in the lung. *Clin Chest Med* 1996;**17**:633-4.
- 32 Ilescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltrative CD8 lymphocytic syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR 5. *Am Intern Med* 1990;**112**:3-10.
- 33 Kazi S, Cohen PR, Williams F, et al. The diffuse infiltrative lymphocytosis syndrome: clinical and immunogenetic features in 35 patients. *AIDS* 1996;**10**:385-91.
- 34 Smith P, Helfbert M, Roferty M. Paraproteins and monoclonal expansion of CD3 CD8 CD56 CD57T lymphocytes in a patient with HIV infection. *Br J Haematol* 1999;**105**:85-7.
- 35 Smith PR, Cavenagh JD, Milner T, et al. Benign monoclonal expansion of CD8+ lymphocytes in HIV infection. *J Clin Pathol* 2000;**53**:177-81.
- 36 Miller R, Bunting S, Saddiq ST, et al. Peripheral neuropathy in HIV infection: think of dual pathology. *Sex Trans Infect* 2002;**78**:462-3.
- 37 Saldana MJ, Montes JM. Lymphoid interstitial pneumonia (LIP) in HIV infection: observations in 52 patients and pathogenesis. *Mod Pathol* 1990;**3**:88A.
- 38 Bienenstock J, Johnston N, Perey D. Bronchial lymphoid tissue. 1: Morphologic characteristics. *Lab Invest* 1973;**28**:686-92.
- 39 Bienenstock J, Johnston N, Perey D. Bronchial lymphoid tissue. 2: Functional characteristics. *Lab Invest* 1973;**28**:693-8.
- 40 Teirstein AS, Rosen MJ. Lymphocytic interstitial pneumonitis. *Clin Chest Med* 1988;**9**:467-71.
- 41 Gould SJ, Isaacson PG. Bronchus associated lymphoid tissue (BAL) in human foetal and infant lung. *J Pathol* 1993;**169**:229-34.
- 42 Richmond I, Pritchard GE, Ashcroft T, et al. Bronchus associated lymphoid tissue (BAL) in human lung: its distribution in smokers and non-smokers. *Thorax* 1993;**48**:1130-4.
- 43 Warren AA, Kelsey M, Arye R, et al. Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. *Lancet* 1985;**2**:1390-3.
- 44 Katz BZ, Berkman RB, Shapiro ED. Serologic evidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. *J Pediatr* 1992;**120**:228-32.
- 45 Barbera JA, Shizu H, Hegele RG, et al. Detection of Epstein-Barr virus in lymphocytic interstitial pneumonitis by in situ hybridization. *Am Rev Respir Dis* 1992;**145**:940-6.
- 46 Reddy A, Lyall EG, Crawford DH. Epstein-Barr virus and lymphocytic interstitial pneumonitis: an association revisited. *Pediatr Infect Dis J* 1998;**17**:82-3.
- 47 Klein C, Rothenberger S, Niemeyer C, et al. EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. *Br J Haematol* 1995;**91**:938-40.
- 48 Kaan PM, Hegele RG, Hayashi S, et al. Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia. *Thorax* 1997;**52**:12-16.
- 49 Hanna Z, Kay DG, Cool M, et al. Transgenic mice expressing HIV type 1 in immune cells develop a severe AIDS like disease. *J Virol* 1998;**72**:121-32.
- 50 Montagnier L, Gruet J, Charmaret S, et al. Adaption of lymphadenopathy associated virus (LAV) to replication in EBV transformed B lymphoblastoid cell lines. *Science* 1984;**225**:63-6.
- 51 Resnick L, Pitchenick AE, Fisher E, et al. Detection of HTLV-III/LAV-specific IgG and antigen in bronchoalveolar lavage fluid from two patients with lymphocytic interstitial pneumonitis associated with AIDS-related complex. *Am J Med* 1987;**82**:553-6.
- 52 Kurosu K, Yumoto N, Rom WN, et al. Aberrant expression of immunoglobulin heavy chain genes in Epstein-Barr virus negative, human immunodeficiency virus related lymphoid interstitial pneumonia. *Lab Invest* 2000;**80**:1891-903.
- 53 Sugimoto M, Mita S, Tokunaga M, et al. Pulmonary involvement in human T-cell lymphotropic virus type-1 uveitis: T-lymphocytosis and high proviral DNA load in bronchoalveolar lavage fluid. *Eur Respir J* 1993;**6**:938-43.
- 54 Yodoi J, Uchiyama T. Diseases associated with HTLV-1: virus, IL2 receptor dysregulation, and redox regulation. *Immunol Today* 1992;**13**:405-10.
- 55 Amorosa J, Miller R, Laraya-Cuasay L, et al. Bronchiectasis in children with lymphocytic interstitial pneumonitis and acquired immunodeficiency syndrome: plain film and CT observations. *Pediatr Radiol* 1992;**22**:603-6.
- 56 Oldham AA, Sandra MC, Jacobson LF, et al. HIV-associated lymphocytic interstitial pneumonia: radiologic manifestations and pathologic correlation. *Thorac Radiol* 1989;**170**:83-7.
- 57 Jonkoh T, Müller NL, Pickford HA, et al. Lymphocytic interstitial pneumonia: thin section CT findings in 22 patients. *Radiology* 1999;**212**:567-72.
- 58 Miller RF, Howling SJ, Ried AJ, et al. Pleural effusions in patients with AIDS. *Sex Trans Infect* 2000;**76**:122-5.
- 59 McGuinness G, Naidich D, Garay S, et al. AIDS associated bronchiectasis: CT features. *JCAT* 1993;**17**:260-6.
- 60 Hwang JH, Lee KS, Rhee CH. Recent advances in radiology of interstitial lung disease. *Curr Opin Pulm Med* 1998;**4**:281-7.
- 61 Jonkoh T, Ichikado K, Akira M, et al. Lymphocytic interstitial pneumonia: follow-up CT findings in 14 patients. *J Thorac Imaging* 2000;**15**:162-7.
- 62 Miller RF. Nuclear medicine and AIDS. *Eur J Nucl Med* 1990;**16**:103-18.
- 63 Kirshenbaum KJ, Burke R, Fanapour F, et al. Pulmonary High resolution tomography versus gallium scintigraphy: diagnostic utility in the diagnosis of patients with AIDS who have chest symptoms and normal equivocal chest radiographs. *J Thorac Imaging* 1998;**13**:52-7.
- 64 Fishback M, Koss M. Update on lymphoid interstitial pneumonitis. *Curr Opin Pulmon Med* 1996;**2**:429-33.
- 65 Malin AS, Miller RF. Pneumocystis carinii pneumonia: presentation and diagnosis. *Rev Med Microbiol* 1992;**3**:80-7.
- 66 Miller RF, Pugsley WB, Griffiths MH. Open lung biopsy for investigation of acute respiratory episodes in patients with HIV infection and AIDS. *Genitourin Med* 1995;**71**:280-5.
- 67 Katzenstein AA. Primary lymphoid lung lesions. In: Katzenstein AA, ed. *Katzenstein and Askin's surgical pathology of non-neoplastic lung disease*. 3rd ed. Philadelphia: WB Saunders, 1997:23-46.
- 68 Colby TV, Koss MN, Travis WD, eds. *Atlas of tumour pathology. Tumours of the lower respiratory tract*. 3rd series. Washington DC: Armed Forces Institute of Pathology, 1994:422-7.
- 69 Hasleton PS. Hypersensitivity pneumonitis. In: Hasleton PS, ed. *Spencer's pathology of the lung*. 5th ed. New York: McGraw-Hill, 1996:1111-29.
- 70 Grieco M and Chinoy-Acharya P. Lymphocytic interstitial pneumonia associated with the acquired immune deficiency syndrome. *Am Rev Resp Dis* 1986;**131**:952-5.

- 71 **Halprin GM**, Ramirez RAJ, Pratt PC. Lymphoid interstitial pneumonia. *Chest* 1972;**62**:418–23.
- 72 **Strobel EJ**, Bonnet RB, Werner P, *et al*. Bronchiolitis obliterans organizing pneumonia (BOOP) and primary biliary cirrhosis (PBC)-like lung involvement in a patient with PBC. *Clin Rheumatol* 1998;**17**:246–9.
- 73 **Solal-Celigny P**, Couderc L, Herman D, *et al*. Lymphoid interstitial pneumonitis in acquired immunodeficiency syndrome-related complex. *Am Rev Resp Dis* 1988;**131**:956–60.
- 74 **Morris JC**, Rosen M, Marchevsky A, *et al*. Lymphocytic interstitial pneumonia in patients at risk for the acquired immunodeficiency syndrome. *Chest* 1978;**91**:63–8.
- 75 **Lin R**, Gruber P, Saunders R, *et al*. Lymphocytic interstitial pneumonitis in adult HIV infection. *NY State J Med* 1988;**88**:273–6.
- 76 **Bach M**. Zidovudine for lymphocytic interstitial pneumonia associated with AIDS. *Lancet* 1987;**2**:796.
- 77 **Helbert M**, Stoneham C, Mitchell D, *et al*. Zidovudine for lymphocytic interstitial pneumonitis in AIDS. *Lancet* 1988;**2**:1333.
- 78 **Campos JM**, Simonette JP. Treatment of lymphoid interstitial pneumonia with chloroquine. *J Pediatr* 1993;**122**:503.
- 79 **BHIVA Writing Committee**, on behalf of the BHIVA Executive Committee. British HIV association (BHIVA) guidelines for the treatment of HIV infected adults with antiretroviral therapy. *HIV Med* 2001;**2**:276–313.

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence based journal available worldwide both as a paper version and on the internet. *Clinical Evidence* needs to recruit a number of new contributors. Contributors are health care professionals or epidemiologists with experience in evidence based medicine and the ability to write in a concise and structured way.

Currently, we are interested in finding contributors with an interest in the following clinical areas:

Altitude sickness; Autism; Basal cell carcinoma; Breast feeding; Carbon monoxide poisoning; Cervical cancer; Cystic fibrosis; Ectopic pregnancy; Grief/bereavement; Halitosis; Hodgkins disease; Infectious mononucleosis (glandular fever); Kidney stones; Malignant melanoma (metastatic); Mesothelioma; Myeloma; Ovarian cyst; Pancreatitis (acute); Pancreatitis (chronic); Polymyalgia rheumatica; Post-partum haemorrhage; Pulmonary embolism; Recurrent miscarriage; Repetitive strain injury; Scoliosis; Seasonal affective disorder; Squint; Systemic lupus erythematosus; Testicular cancer; Varicocele; Viral meningitis; Vitiligo

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Appraising the results of literature searches (performed by our Information Specialists) to identify high quality evidence for inclusion in the journal.
- Writing to a highly structured template (about 2000–3000 words), using evidence from selected studies, within 6–8 weeks of receiving the literature search results.
- Working with *Clinical Evidence* Editors to ensure that the text meets rigorous epidemiological and style standards.
- Updating the text every eight months to incorporate new evidence.
- Expanding the topic to include new questions once every 12–18 months.

If you would like to become a contributor for *Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Claire Folkes (cfolkes@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are health care professionals or epidemiologists with experience in evidence based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and health care professionals, possibly with limited statistical knowledge). Topics are usually 2000–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for *Clinical Evidence*, please complete the peer review questionnaire at www.clinicalevidence.com or contact Claire Folkes (cfolkes@bmjgroup.com).